$VBIO

3i, LP and related parties report a 9.99% passive stake in Valion Bio (VBIO), owning 132,671 shares. The position includes 90,252 direct shares and up to 42,419 additional shares from convertibles and warrants, all subject to a 9.99% ownership cap. The investors amended their filing from a control-oriented 13D to a passive 13G, indicating no intent to influence control. Figures reflect VBIO's 1-for-25 reverse stock split.

Valion Bio, Inc. (VBIO) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 FOR IMMEDIATE RELEASE Valion Bio Announces Changes to Management and Board of Directors Current CFO, Lisa Wolf named President and COO, assuming expanded executive and operational leadership. Jared Malbin and Thomas Jensen appointed as directors. · Lead Asset Positio

Valion Bio (VBIO) implemented a 1-for-20 reverse stock split on August 31, 2026, to meet Nasdaq's minimum bid price requirement. Trading continues under the same symbol with a new CUSIP. The split does not alter ownership percentages, voting rights, or share counts. VBIO's stock is up 10.27% to $3.32.

Valion Bio, Inc. (Nasdaq:VBIO) announced a 1-for-25 reverse stock split to comply with Nasdaq's minimum bid price requirement. The split, approved by shareholders, will take effect on August 31, 2026, and trading will resume under the same symbol. The company aims to regain compliance and maintain its Nasdaq listing.

Valion Bio, Inc. (VBIO) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 1.01 Entry into a Material Definitive Agreement The Company and 3i, LP (“3i”) are parties to that certain Securities Purchase Agreement, dated April 29, 2025 (as assigned and amended as of December 9, 2025, the “Series B Preferred Purchase Agreement”), with respect to the pu

Valion Bio (Nasdaq:VBIO) said Ukraine’s Ministry of Health accepted its Entolimod dossier for formal review on July 22, 2026, and started a technical assessment with questions on physicochemical characterization for a potential stockpiling supply. The company expects a possible decision as early as Q4 2026, which could enable national registration and potential future government procurement, though no deal is signed.

Valion Bio (Nasdaq:VBIO) said AFRRI, under a contract with NIAID, is running U.S. government-funded studies of Entolimod for radiation-induced GI injury. A safety study is planned to start this week, followed by a therapeutic study with top-line data expected in early fall. The program aims to assess survival and GI recovery after lethal radiation doses.

Valion Bio, Inc. (VBIO) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. Securities Purchase Agreement On July 31, 2026, the Company issued an aggregate of 1,287.8685 shares of Series A Preferred Stock (“Milestone Shares”), as consideration for the Milestone Payment (as discussed in more detail in

Valion Bio, Inc. (VBIO) filed an SEC Form 8-K — Unregistered Sales of Equity Securities. Tivic Health Systems, Inc. Form 8-K false 0001787740 0001787740 2026-06-17 2026-06-17 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securitie